Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis

Allergy. 2021 Apr;76(4):1268-1270. doi: 10.1111/all.14664. Epub 2020 Dec 16.

Authors

Maria Helena Rohner¹, Kathrin Thormann¹, Simone Cazzaniga^{1

2}, Shida Yousefi³, Hans-Uwe Simon^{3

4}, Christoph Schlapbach¹, Dagmar Simon¹

Affiliations

¹ Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
² Centro Studi GISED, Bergamo, Italy.
³ Institute of Pharmacology, University of Bern, Bern, Switzerland.
⁴ Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia.

PMID: 33210741
DOI: 10.1111/all.14664

No abstract available

Keywords: atopic dermatitis; dupilumab; epidermal barrier; interleukin-13; type 2 inflammation.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Dermatitis, Atopic* / drug therapy
Humans
Inflammation
Interleukin-13

Substances

Antibodies, Monoclonal, Humanized
Interleukin-13
dupilumab